Pharmacotherapy of type 2 diabetes: An update.
| Title | Pharmacotherapy of type 2 diabetes: An update. |
| Publication Type | Journal Article |
| Year of Publication | 2018 |
| Authors | Upadhyay, J., Polyzos S. A., Perakakis N., Thakkar B., Paschou S. A., Katsiki N., Underwood P., Park K-H., Seufert J., Kang E. Seok, Sternthal E., Karagiannis A., & Mantzoros C. S. |
| Journal | Metabolism |
| Volume | 78 |
| Pagination | 13-42 |
| Date Published | 2018 01 |
| ISSN | 1532-8600 |
| Keywords | Animals, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents |
| Abstract | Type 2 diabetes (T2DM) is a leading cause of morbidity and mortality worldwide and a major economic burden. The prevalence of T2DM is rising, suggesting more effective prevention and treatment strategies are necessary. The aim of this narrative review is to summarize the pharmacologic treatment options available for patients with T2DM. Each therapeutic class is presented in detail, outlining medication effects, side effects, glycemic control, effect on weight, indications and contraindications, and use in selected populations (heart failure, renal insufficiency, obesity and the elderly). We also present representative cost for each antidiabetic category. Then, we provide an individualized guide for initiation and intensification of treatment and discuss the considerations and rationale for an individualized glycemic goal. |
| DOI | 10.1016/j.metabol.2017.08.010 |
| Alternate Journal | Metab. Clin. Exp. |
| PubMed ID | 28920861 |
